Although new U.S. tariffs on Canada, Mexico, and China are putting pressure on markets, investors are shifting toward ...

2seventy bio worked with BMS on the development of BCMA-directed CAR-T therapy Abecma (idecabtagene vicleucel), used to treat ...

The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.

Bristol Myers Squibb buys 2seventy bio for $286 million, strengthening its cancer portfolio with Abecma CAR-T therapy for ...

The deal includes an undisclosed upfront payment from BMS, with GentiBio also in line to receive milestone payments of up to $1.9 billion, as well as royalties on any future sales. The partners ...

At one point, BMS said the facility would house 400 people. That was before Chairman and CEO Chris Boerner replaced Giovanni ...

Shortly after bringing in a former FDA official to serve as its chief medical officer, Pfizer’s latest leadership appointment ...

In other words, for those looking for "forever stocks," it's not a bad idea to look in this sector. And even with a modest sum -- such as $200 -- we can find excellent healthcare corporations to ...

In connection with the execution of the merger agreement, certain stockholders of 2seventy bio owning approximately 5.3% of the outstanding shares of 2seventy bio’s common stock have entered into ...

The deal comes after a challenging few years for 2seventy bio, which had divested research programmes in recent years.

Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...

Ongoing strategic partnership advances joint pipeline in neurodegeneration research Evotec receives a $20 million payment to ...